



PATENT
Atty. Docket No. 1534.209

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Verena Huebner et al.

Serial No.: 10/757,347 Group Art Unit: 1626

Filed: January 13, 2004 Examiner: L. Stockton

For: ESTROGEN RECEPTOR MODULATORS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56, §1.97 AND §1.98

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

The citations listed on the enclosed Supplemental Information Disclosure Form PTO-1449 may be material to the examination of the above-identified patent application. Therefore, Applicants submit these documents in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56, §1.97 and §1.98. The Examiner is requested to make these citations of official record in the present application.

The present Supplemental Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits. Therefore, Applicants enclose herewith the \$180.00 fee set forth under §1.17(p).

This Supplemental Information Disclosure Statement under 37 C.F.R. §1.56, §1.97 and §1.98 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 U.S.C. §102 or §103.

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class mail in an envelope addressed to: Mail Stop _____
Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450,
on this 22 day of February 2004.
By Verena Huebner

PATENT
Atty. Docket No. 1534.209

The Commissioner is hereby authorized to charge any additional fees in connection with this Supplemental Information Disclosure Statement to Deposit Account No. 03-1664. This, however, is not an authorization to pay Issue Fee.

Respectfully submitted,

By:



Steven W. Collier
Attorney for Applicants
Reg. No. 42,429

November 22, 2004

CHIRON CORPORATION
Intellectual Property - R440
P.O. Box 8097
Emeryville, California 94662-8097
(510) 923-3774
(510) 655-3542 (fax)

FORM PTO-1449 (Modified)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No.: 1534.209	Serial No.: 10/757,347
INFORMATION DISCLOSURE CITATION		Applicants: Huebner et al.	
(Use several sheets if necessary)		Filing Date: January 13, 2004	Group: 1626

U. S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Publ. Date	Country	Class	Subclass	Trans- Yes	lation No
	BA	418,845 B1	03/27/91	EP				
	BB	442,448 A2	08/21/91	EP				
	BC	WO 92/06962	04/30/92	PCT				
	BE	WO 95/15316	06/08/95	PCT				
	BE	WO 95/15318	06/08/95	PCT				
	BF	WO 96/15115	05/23/96	PCT				
	BG	WO 97/14679	04/24/97	PCT				

OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA		Omar et al., "Synthesis, Binding Affinities and Uterotrophic Activity of Some 2-Substituted Estradiol and Ring-A-Fused Pyrone Derivatives" <u>Eur. J. Med. Chem.</u> 29:25-32, 1994
CB		Bass and Srinivasan, "Synthesis of Poly(Arylene Ether-Pyrazoles) by Aromatic Nucleophilic Displacement Reactions" <u>Polymer Preprints (AMS)</u> 32(1):619-620
CC		Bass and Srinivasan, "Synthesis of Novel Fluorine Containing Poly(Arylene Ether-Pyrazoles)" <u>Polymer Preprints (AMS)</u> 34(1):441-442, 1993
CD		Eldin et al., "Hydazidoly Halides in Heterocyclic Synthesis: Systhesis of Several New Polyfunctional Pyrazole . . ." <u>Egypt. J. Pharm. Sci.</u> 37(1-6):351-362, 1996
CE		Jerzmanowska et al., "Glikozyd 3-Acetylo-4-Hydroksyflawonu I Jego Przemiany" <u>Roczniki Chemii</u> 42(12):2113-2119, 1968
CF		Youssef et al., "Synthesis and Mass Spectral Studies of Some 1-[2-Benzimidazolyl] or [6-Methyl-4-(1H)-Pyrimidinon-2-yl]-5-Substituted phenyl-3-Methylpyrazoles" <u>Egypt. J. Pharm. Sci.</u> 33(5-6):1099-1108, 1992

Examiner	Date Considered
----------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.